



## **Iveric Bio to Report First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019**

May 1, 2019

NEW YORK--(BUSINESS WIRE)--May 1, 2019-- [IVERIC bio](#) (Nasdaq:ISEE) today announced that it will report its first quarter 2019 financial and operating results on Wednesday, May 8, 2019. Following the announcement, IVERIC bio's management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update.

To participate in this conference call, dial 888-224-1005 (USA) or 323-794-2551 (International), passcode 9765307. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the IVERIC bio website at [www.ivericbio.com](http://www.ivericbio.com). A replay will be available approximately two hours following the live call for two weeks. The replay number is 888-203-1112 (USA Toll Free), passcode 9765307.

### **About IVERIC bio**

IVERIC bio is a biotechnology company with a focus on the discovery and development of novel gene therapy solutions to treat orphan inherited retinal diseases with unmet medical needs. Vision is Our Mission. For more information on the Company's gene therapy and other programs, please visit [www.ivericbio.com](http://www.ivericbio.com).

### **Forward-looking Statements**

*Any statements in this press release about IVERIC bio's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent IVERIC bio's views only as of the date of this press release. IVERIC bio anticipates that subsequent events and developments will cause its views to change. While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.*

### **ISEE-G**

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190501005023/en/>

Source: IVERIC bio

### **Investor:**

Kathy Galante  
IVERIC bio  
Vice President, Investor Relations and Corporate Communications  
212-845-8231  
[kathy.galante@ivericbio.com](mailto:kathy.galante@ivericbio.com)

### **Media:**

Alex Van Rees  
SmithSolve LLC on behalf of IVERIC bio  
973-442-1555 ext. 111  
[alex.vanrees@smithsolve.com](mailto:alex.vanrees@smithsolve.com)